VistaGen has developed a stem cell technology platform based on the controlled transformation of human pluripotent stem cells into mature human cells, which can then be used to create bioassay systems to provide clinically relevant predictions on the toxicity and metabolism issues of promising new drug candidates before they are ever tested in human subjects.
The company sees a huge disadvantage to the pharmaceutical industry in that conventional animal and in vitro cell culture testing only approximates human biology, generating risk for failed drug candidates and wasted resources.
VistaGen leverages its Human Clinical Trials in a Test Tube™ platform to mitigate such losses and to revive once-promising small drug molecule candidates that failed in the development process due to heart or liver toxicity or metabolism issues.
Human Clinical Trials in a Test Tube™ is based on a combination of proprietary and exclusively licensed stem cell technologies, some of which were developed over the past two decades by co-founders and renowned Canadian stem cell scientist Dr. Gordon Keller and company president and Chief Scientific Officer Dr. Ralph Snodgrass.
Backed with such expertise and technology, the company only focuses on discontinued drug candidates with positive preclinical efficacy data to identify and develop new, safe drug rescue variants in a faster and less expensive manner than drug candidates discovered and developed using animal studies, and in vitro cell culture testing systems.
For more information, visit www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
